| Annual ASCO Meeting
I am looking forward to seeing many of you at ASCO next week. Below is a list of Yale Cancer Center presentations and poster sessions scheduled. If your schedule permits, I hope you will take time to add these to your agenda.
Friday, June 4th; 2:00 - 6:00 PM; Location: E450a
Poster Session
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial.
Francine Foss, MD
Saturday, June 5th; 12:00 - 1:00 PM; Location: E354b
Poster Discussion Session
A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).
Maysa Abu-Khalaf, MD
Saturday, June 5th; 2:00 - 6:00 PM; Location: S Hall A2
Poster Session
Cisplastin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma.
Hao Wang, MD, PhD
Saturday, June 5th; 5:00 - 6:00 PM; Location: S100a
Poster Discussion Session
Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer.
Maria Baquero
Sunday, June 6th; 8:00 - 9:15 AM; Location: E451a
Clinical Problems in Oncology Session
Impact of T-Cell Directed Therapies on Immunocompetence
Francine Foss, MD
Sunday, June 6th; 8:00 AM - 12:00 PM; Location: S Hall A2
Poster Session
Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA.
Eirini Pectasides, MD
Sunday, June 6th; 5:00 - 6:00 PM; Location: E Arie Crown Theater
Poster Discussion Session
A KRAS-variant as a biomarker of ovarian cancer risk.
Joanne Weidhaas, MD, PhD
Monday, June 7th; 8:00 AM - 12:00 PM; Location: S Hall A2
Trials in Progress Poster Session
A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer.
Roy Decker, MD, PhD
Monday, June 7th; 8:00 AM - 12:00 PM; Location: S Hall A2
Trials in Progress Poster Session
Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.
Geoffrey Gibney, MD
Monday, June 7th; 8:00 AM - 12:00 PM; Location: S Hall A2
Trials in Progress Poster Session
Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma.
Jia Li, MD, PhD
Monday, June 7th; 12:00 - 1:00 PM; Location: E Hall D1
Poster Discussion Session
Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
Thomas Lynch, Jr., MD
Monday, June 7th; 1:00 - 5:00 PM; Location: S Hall A2
General Poster Session
Protocol Performance and Resource Utilization of Phase II Investigator-Initiated Trials.
Henry Durivage, PharmD
Monday, June 7th; 1:00 - 5:00 PM; Location: S Hall A2
General Poster Session
A phase II study of oral phenoxodiol in castrate and noncastrate prostate cancer patients with associated cytokine changes.
Geoffrey Gibney, MD
Tuesday, June 8th; 9:30 AM - 12:30 PM; Location: E354a
Oral Abstract Session
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.
Mario Sznol, MD
UCL Collaboration
We are excited to begin collaborating with University College London (UCL) through Yale University and Yale-New Haven Hospital's partnership in research and clinical care with UCL. 10 members of Yale Cancer Center will travel to the UCL Cancer Institute in July to present research from Yale and meet potential collaborators. The following presentations are scheduled for July 12th and 13th in London:
Thomas Lynch : Targeted Therapy of Lung Cancer 2010
Xiaomei Ma : Etiologic and Outcomes Research of Hematological Malignancies
Kenneth Kidd : Population Genetics of Genes with Variation
Affecting Risk of Cancer
Cary Gross : Understanding Cancer Screening and Outcomes in an Aging Population
M. Tish Knobf : Weight, Body Composition, and Physical Activity in Breast Cancer Survivors
Daniel DiMaio : Traptamers: Small Artificial Transmembrane
Proteins that Regulate Cellular and Viral Behavior
James Noonan : Next-generation Sequencing Strategies to Study Cellular Differentiation in vivo
Warren Shlomchik : Minor Histocompatibility Antigen Vaccination to Augment Graft-vs-Leukemia
Diane Krause : MKL1/SRF in Acute Leukemia and Myelodysplasia
Michael Krauthammer : Real-Time Cancer Data Sharing: Are We There Yet?
David Stern : Integrated Genome, Kinome, and Functional Analyses for Melanoma Treatment
|
John Wysolmerski, MD received a Breast Cancer Idea Award from the
Department of Defense Breast Cancer Research Program for $375,000 to study the "Effects of Nuclear Parathyroid Hormone-Related Protein Signaling in Breast Cancer." The project will examine the effects of nuclear PTHrP signaling on the development and progression of tumors in MMMTV-Wnt 1 mice and use tissue microarray techniques to determine if nuclear PTHrP staining in primary breast tumors correlates witht he clinical outcome of breast cancer patients. The research will be done in collaboration with
Joshua VanHouten, PhD , and
David Rimm, MD, PhD .
Nita Maihle, PhD
received a $75,000 grant from the
Harry J. Lloyd Charitable Trust to fund a pilot study entitled "A Preclinical Study of p45-sHER3: A Putative Metastasis Factor in Melanoma." The research will biologically characterize HER3, sHER3, and heregulin in melanocyte-derived cell lines. p45-sHER3 was discovered in Dr. Maihle's laboratory, and has been shown to be a key bone-specific metastasis factor in prostate cancer. Her collaborators on this study are Dr. Yingqun Huang and Ms. Ti Badri.
|
AACR Gertrude B. Elion Cancer Research Award
The AACR Gertrude B. Elion Award is open to tenure-track scientists at the level of Assistant Professor working at an academic, medical, or research institution who completed postdoctoral studies or clinical fellowships no more than five years prior to the start of the grant term. Proposed research projects may focus on research in cancer etiology, diagnosis, treatment, or prevention (basic, translational, or clinical cancer research). One,1-year grant of $50,000 will be awarded.
Application Deadline: June 7, 2010 at 12:00 noon, Eastern Time
Learn More >>
Breast Cancer Research Foundation-AACR Grants for Translational Breast Cancer Research
The BCRF-AACR Grants for Translational Breast Cancer Research is open to independent investigators who are affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world. Proposed research projects must focus on innovative cancer research, designed to accelerate the discovery, development, and application of new agents to treat breast cancer and/or for pre-clinical research with direct therapeutic intent. Two, 2-year grants of $181,000 will be awarded.
Application Deadline: June 7, 2010
Learn More >>
Ovarian Cancer Research Fund Program Project Grant
Program Project Development Grant
The purpose of this program is to provide funds for ovarian cancer research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. The primary review criteria will be the likelihood that the investigators can leverage this funding to compete successfully for an NCI or DOD funded program project grant, SPORE or similar award in the future. Support of $300,000 annually for three years will be awarded to the institution(s) in which the recipients will conduct the research.
Application Deadline: June 25, 2010
Learn More >>
Liz Tilberis Scholars Program
The Liz Tilberis Scholars Program is directed towards junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research. The intent of these awards is to support a substantial time commitment to research and academic endeavors in ovarian cancer.
Application Deadline: June 25, 2010
Learn More >>
Ann Schreiber Research Training Programs of Excellence
Purpose: The Ovarian Cancer Research Fund's Ann Schreiber Research Training Programs of Excellence provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research.
Application Deadline: June 25, 2010
Learn More >>
|
Psycho-Oncology Research Program
The newly created Psycho-Oncology Research Program is a component of the Yale Cancer Center Cancer Prevention and Control Research Program. Led by Ruth McCorkle, Assistant Director for Psycho-Oncology, the program conducts psycho-oncology research and promotes the translation of psycho-oncology research to patient-centered care.
Purposes: - Develop an interdisciplinary program of psycho-oncology research at Yale Cancer Center
- Design and implement psycho-oncology research
- Facilitate the translation of psycho-oncology research to clinical practice at Smilow Cancer Hospital
- Develop a pre- and post-doctoral training program in psycho-oncology research
Proposed Research Projects to be conducted at Smilow Cancer Hospital: - Smoking Cessation Program - Benjamin Toll
- Psychological Screening for Distress - Bonnie Indeck, Dwain Fehon, Leslie Blatt, and Ruth McCorkle
- Discharge Screening for High-Risk Patients at Discharge for Re-Hospitalization - Ruth McCorkle and Kathy Tynan-McKiernan
If you have interest in participating in this research program, please contact Ruth McCorkle.
|
Join us at the Connecticut Challenge
Join the team "Yale, Smilow and Friends" for the 6th annual Connecticut Challenge. All ages and abilities are welcome to ride. Now in its 6th year, the Connecticut Challenge is an annual ride with participants choosing distances of 12, 25, 50, 75 and 100 miles.
This year's ride begins and ends in Fairfield on Saturday, July 24, 2010. Many throughout the Yale community have ridden in past years and we invite you to join us again or for the first time! Bikes are available for rent at the ride. Please read all the ride and fundraising information carefully and if you choose to ride, please join the team "Yale, Smilow and Friends." If you wish to simply support the team with a donation, please do so!
Learn More >>
Team Tri-Captains:
Melinda Irwin
Robert Dubrow
Peter Lamothe
|
Recent Publications
Targeted therapy for thyroid cancer: An updated review of investigational agents.
Deshpande HA, Gettinger SN, Sosa JA.
Curr Opin Investig Drugs. 2010 Jun;11(6):661-8.
Read More >>
Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation.
Wysolmerski JJ.
Ann N Y Acad Sci. 2010 Mar;1192(1):161-9.
Read More >>
The dual nature of T(H)17 cells: shifting the focus to function.
O'Connor W Jr, Zenewicz LA, Flavell RA.
Nat Immunol. 2010 Jun;11(6):471-6.
Read More >>
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer.
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC.
J Clin Oncol. 2010 May 17.
Read More >>
Hypersensitivity vasculitis associated with leuprolide (Lupron).
Gnanaraj J, Saif MW.
Cutan Ocul Toxicol. 2010 May 17.
Read More >>
Comparative Effectiveness Research: What Kind of Studies Do We Need?
Concato J, Peduzzi P, Huang GD, O'Leary TJ, Kupersmith J.
J Investig Med. 2010 May 14.
Read More >>
A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system.
Brodsky IE, Palm NW, Sadanand S, Ryndak MB, Sutterwala FS, Flavell RA, Bliska JB, Medzhitov R.
Cell Host Microbe. 2010 May 20;7(5):376-87.
Read More >>
Blueprint for the dissemination of evidence-based practices in health care.
Yuan CT, Nembhard IM, Stern AF, Brush JE Jr, Krumholz HM, Bradley EH.
Issue Brief (Commonw Fund). 2010 May;86:1-16.
Read More >>
Atypical Cystic Carcinoid Tumors of the Liver.
Salamone L, McCarthy S, Salem RR.
J Clin Gastroenterol. 2010 May 11.
Read More >>
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
Rowe BP, Glazer PM.
Breast Cancer Res. 2010 Apr 30;12(2):203.
Read More >>
|
| |
|
Inside Yale Cancer Center
Personal Perspective with Dr. Gary Friedlaender
Oncology Congress 2010
Yale Cancer Center is a partner for this year's congress.
Subscribe to Yale Cancer Center Answers on iTunes
Yale Cancer Center's weekly radio program on CT Public Radio is ranked number 2 in the world for cancer programs on iTunes.
Learn More >>
Cancer Bytes
Hosted by Ellen Matloff, listen to the interviews online.
Learn More >>
Yale Cancer Center Grand Rounds
Video presentations from Yale Cancer Center members are now available online.
Learn More >>
DirectConnect Archives
Learn More >>
|
Events
May 30; 6:00 PM
Yale Cancer Center Answers
WNPR 90.5
Breast Cancer
Michael DiGiovanna, MD, PhD
Learn More >>
June 1; 12:00 PM
Yale Cancer Center Grand Rounds
55 Park Street
Thyroid Cancer and the Controversy Currently Surrounding Neck Dissection
Robert Udelsman, MD
Who Moved My Stage? Reacting to Changes in the Lung Cancer Staging System
Daniel Boffa, MD
Learn More >>
June 1; 5:00 PM
Breast Cancer Clinical Seminar Series
WWW 208
Modern Management of Axilia in Breast Cancer Patients
Brigid Killelea
June 6; 6:00 PM
Yale Cancer Center Answers
WNPR 90.5
Lymphoma
Francine Foss, MD
Learn More >>
June 9; 4:00 PM
Epigenetics Interest Group Meeting
BML 147
Tian Chi Lab Presenting
June 11; 12:30 PM
Molecular Virology Research Program Conference
SHM I-116
Antibody-Recruiting Small Molecules to Target HIV and Other Pathogens
David Spiegel, MD, PhD
|
Submissions
Please submit your recent publication and grant announcements to:
Renee Gaudette
Director, Public Affairs and Marketing
renee.gaudette@yale.edu
|
|
|
